Geroscience is a research paradigm based in understanding the genetic, molecular and cellular mechanisms that make aging a major risk factor for and driver of common chronic conditions and diseases of older people. Geroscience research seeks to understand how aging affects the disease process and to use that knowledge to slow the rate of aging, reverse its effects, and delay or even cure age-related diseases.

The Translational Geroscience Network (TGN) is a collaboration of researchers looking at clinical interventions that target fundamental mechanisms of aging to delay, prevent or treat age-related diseases and disabilities as a group, instead of one at a time.

Network Clinical Trials

The Translational Geroscience Network (TGN) maintains this list of clinical trials in which the network is directly involved. This list is dynamically updated with detail provided by clinicaltrials.gov to showcase the network's progress, collaboration and expansion. This list can be searched or exported as a spreadsheet.

NCT # Title Acronym Status Publications Stored Specimens Conditions Interventions Outcome Measures Sponsor Collaborators Gender Age Phases Enrollment Funded Bys Study Type Study Designs Other IDs Start Date Primary Completion Date Completion Date First Posted Results First Posted Last Update Posted Locations Study Documents URL
NCT04785300 ALSENLITE: Senolytics for Alzheimer's Disease Enrolling by invitation Mild Cognitive Impairment|Alzheimer Disease Drug: Dasatinib|Drug: Quercetin Safety and Tolerability of 11 week of intermittent D+Q treatment James L. Kirkland, MD, PhD|Mayo Clinic All 55 Years and older   (Adult, Older Adult) Phase 1|Phase 2 20 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 19-003394 October 2021 December 2022 June 2023 March 5, 2021 October 6, 2021 Mayo Clinic in Rochester, Rochester, Minnesota, United States https://ClinicalTrials.gov/show/NCT04785300
NCT04733534 An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer Not yet recruiting Frailty|Childhood Cancer Drug: Dasatinib plus Quercetin|Drug: Fisetin Change in walking speed|Change in Walking Speed|Senescent cell abundance in blood (p16INK4A)|Safety of two different senolytic therapies as assessed by treatment-related adverse events using CTCAE v5.0|Tolerability of two different senolytic therapies as assessed by treatment-related adverse events using CTCAE v5.0 St. Jude Children's Research Hospital|National Institutes of Health (NIH)|National Cancer Institute (NCI) All 18 Years and older   (Adult, Older Adult) Phase 2 60 Other|NIH Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment SENSURV|U01CA246510 October 2021 July 2023 July 2024 February 2, 2021 September 10, 2021 St. Jude Children's Research Hospital, Memphis, Tennessee, United States https://ClinicalTrials.gov/show/NCT04733534
NCT04537299 COVID-FIS: Pilot in COVID-19 (SARS-CoV-2) of Fisetin in Older Adults in Nursing Homes COVID-FIS Enrolling by invitation Covid19|SARS-CoV Infection Drug: Fisetin|Drug: Placebo Change in COVID-19 Severity Mayo Clinic|National Institute on Aging (NIA) All 65 Years and older   (Older Adult) Phase 2 150 Other|NIH Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment 20-008867|1R01AG072301-01 October 2021 December 2023 December 2023 September 3, 2020 October 6, 2021 Mayo Clinic, Rochester, Minnesota, United States https://ClinicalTrials.gov/show/NCT04537299
NCT04476953 COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation Enrolling by invitation Covid19 Drug: Placebo|Drug: Fisetin Serious Adverse Events|Change in oxygenation status|CoV Severity Category Mayo Clinic All 18 Years and older   (Adult, Older Adult) Phase 2 70 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment 20-003936 August 3, 2020 January 2022 July 2022 July 20, 2020 August 12, 2021 Mayo Clinic in Rochester, Rochester, Minnesota, United States https://ClinicalTrials.gov/show/NCT04476953
NCT04313634 Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans Recruiting Healthy Drug: Dasatinib|Drug: Quercetin|Drug: Fisetin Percent Changes in C-terminal telopeptide of type I collagen [CTX]|Percent Changes in amino-terminal propeptide of type I collagen [P1NP] Sundeep Khosla, M.D.|Mayo Clinic Female 70 Years and older   (Older Adult) Phase 2 120 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care 18-010546 June 9, 2020 April 30, 2022 March 31, 2023 March 18, 2020 July 21, 2021 Mayo Clinic in Rochester, Rochester, Minnesota, United States https://ClinicalTrials.gov/show/NCT04313634
NCT04176133 Entolimod on Immunosenescence in Healthy Geriatric Subjects Receiving Influenza Vaccination Active, not recruiting Healthy Drug: Entolimod|Drug: Placebo Immunogenicity|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] Mayo Clinic|Genome Protection, Inc All 65 Years and older   (Older Adult) Phase 2 100 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention 19-004847 October 30, 2019 March 30, 2022 April 30, 2022 November 25, 2019 June 1, 2021 Mayo Clinic in Rochester, Rochester, Minnesota, United States https://ClinicalTrials.gov/show/NCT04176133
NCT04063124 Senolytic Therapy to Modulate Progression of Alzheimer's Disease SToMP-AD Recruiting Alzheimer Disease Drug: Dasatinib + Quercetin Brain penetrance of Dasatinib (D)|Brain penetrance of Quercetin (Q)|Alzheimer's Disease marker - CSF tau|Alzheimer's Disease marker - CSF amyloid beta|Senescence marker IL-6 in CSF|Senescence marker P16 in CSF|Electronic gait mapping under single and dual-task conditions|Montreal Cognitive Assessment (MoCA) The University of Texas Health Science Center at San Antonio|Mayo Clinic All 65 Years and older   (Older Adult) Phase 1|Phase 2 5 Other Interventional Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment HSC20190222H February 14, 2020 August 2022 August 2023 August 21, 2019 June 21, 2021 Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, San Antonio, Texas, United States https://ClinicalTrials.gov/show/NCT04063124
NCT03675724 Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Adults AFFIRM-LITE Recruiting Frail Elderly Syndrome Dietary Supplement: Fisetin|Drug: Placebo oral capsule Decrease in blood inflammation markers Mayo Clinic All 70 Years and older   (Older Adult) Phase 2 40 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment 18-007332 November 15, 2018 September 28, 2021 November 28, 2021 September 18, 2018 February 24, 2021 Mayo Clinic in Rochester, Rochester, Minnesota, United States https://ClinicalTrials.gov/show/NCT03675724
NCT04235309 Physical Resilience: Indicators and Mechanisms in the Elderly (PRIME) Collaborative Phase 2 PRIME-Knee Recruiting Resilience|Aging Change in musculoskeletal resiliency following orthopedic surgery as measured by physical activity (step counts)|Change in musculoskeletal resiliency following orthopedic surgery as measured by Lower Extremity Physical Activities of Daily Living (LE PADLs)|Change in musculoskeletal resiliency following orthopedic surgery as measured by PROMIS Pain Intensity|Change in musculoskeletal resiliency following orthopedic surgery as measured by PROMIS Pain Interference|Change in cognitive resiliency following orthopedic surgery as measured by 3D-CAM.|Change in cognitive resiliency following orthopedic surgery as measured by cognitive change index (CCI) for patient.|Change in cognitive resiliency following orthopedic surgery as measured by cognitive change index (CCI) for informant about patient.|Change in association between in vitro immune resiliency and resilient outcomes following elective orthopedic surgery.|Change in dual task gait speed|Change in tissue oxygenation index (TOI)|Intraoperative electrocardiography (ECG) RR variability Duke University|National Institute on Aging (NIA) All 60 Years and older   (Adult, Older Adult) 250 Other|NIH Observational Observational Model: Cohort|Time Perspective: Prospective Pro00103483|4UH3AG056925-03 February 27, 2020 February 27, 2023 February 27, 2023 January 21, 2020 March 11, 2021 Duke Regional Hospital, Durham, North Carolina, United States|Duke University Hospital, Durham, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States https://ClinicalTrials.gov/show/NCT04235309
NCT03430037 Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women AFFIRM Recruiting Frail Elderly Syndrome Dietary Supplement: Fisetin|Drug: Placebo oral capsule Improved 6 minute walk Mayo Clinic Female 70 Years and older   (Older Adult) Phase 2 40 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment 17-000472 February 6, 2018 December 31, 2021 June 30, 2022 February 12, 2018 February 24, 2021 Mayo Clinic in Rochester, Rochester, Minnesota, United States https://ClinicalTrials.gov/show/NCT03430037
NCT03325322 Inflammation and Stem Cells in Diabetic and Chronic Kidney Disease Recruiting Chronic Kidney Diseases|Diabetes Mellitus|Diabetic Nephropathies Dietary Supplement: Fisetin|Drug: Placebo oral capsule Change in inflammatory markers including C-reactive protein|Effect on Mesenchymal stem cell function including cell migration|Effect on measures of Frailty including Fried Criteria|Kidney function including estimated glomerular filtration rate|Kidney function including urine protein excretion rate|Number of participants with treatment-related adverse events including hospitalization Mayo Clinic All 40 Years to 80 Years   (Adult, Older Adult) Phase 2 30 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment 16-010521 January 2, 2018 January 2023 April 2025 October 30, 2017 September 14, 2021 Mayo Clinic in Rochester, Rochester, Minnesota, United States https://ClinicalTrials.gov/show/NCT03325322
NCT02874989 Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial IPF Completed PMID: 30616998   Idiopathic Pulmonary Fibrosis (IPF) Drug: Dasatinib + Quercetin|Drug: Placebo Percentage of pro-inflammatory expressing cells|Blood Pressure|Weight|Heart Rate|CBC (complete blood count)|Lipid Panel|HbA1c (glycated hemoglobin)|CMP (comprehensive metabolic panel)|Plasma hsCRP (high-sensitivity C-reactive protein)|Plasma IL-6 (inflammatory biomarker)|Plasma IL-6R (inflammatory biomarker)|Plasma PASP biomarkers (inflammatory biomarkers)|p16INK4a biomarker (inflammatory biomarker) Wake Forest University Health Sciences|Mayo Clinic|The University of Texas Health Science Center at San Antonio All 50 Years and older   (Adult, Older Adult) Phase 1 26 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science IRB00037000 December 16, 2016 June 3, 2019 June 3, 2019 August 22, 2016 May 12, 2020 Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|University of Texas Health Science Center, San Antonio, Texas, United States "Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/89/NCT02874989/ICF_000.pdf https://ClinicalTrials.gov/show/NCT02874989
NCT02848131 Senescence in Chronic Kidney Disease Enrolling by invitation Chronic Kidney Disease Drug: Group 2: Dasatinib|Drug: Group 2: Quercetin Change in proportion of senescent cells (representing the total senescent cell burden) present|Change in proportion of senescent mesenchymal stem cells present|Change in mesenchymal stem cell function|Change in Frailty index score|Change in kidney function Mayo Clinic All 40 Years to 80 Years   (Adult, Older Adult) Phase 2 30 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 15-005843 July 2016 April 2, 2022 June 2, 2022 July 28, 2016 August 12, 2021 Mayo Clinic in Rochester, Rochester, Minnesota, United States "Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/31/NCT02848131/Prot_SAP_001.pdf https://ClinicalTrials.gov/show/NCT02848131
NCT02652052 Hematopoietic Stem Cell Transplant Survivors Study (HTSS Study) HTSS Recruiting Stem Cell Transplant Drug: Quercetin|Other: Standard of Care - Observation Only|Drug: Dasatinib Frailty Mayo Clinic All 18 Years and older   (Adult, Older Adult) Not Applicable 10 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment 15-004683 March 2016 December 2021 December 2021 January 11, 2016 April 6, 2021 Mayo Clinic in Rochester, Rochester, Minnesota, United States https://ClinicalTrials.gov/show/NCT02652052
NCT04771611 COVFIS-HOME: COVID-19 Pilot Study of Fisetin to Alleviate Dysfunction and Decrease Complications COVFIS-HOME Enrolling by invitation Covid19|Coronavirus Infection Drug: Fisetin Serious Adverse Events|Long Hauler Syndrome James L. Kirkland, MD, PhD|Mayo Clinic All 18 Years and older   (Adult, Older Adult) Phase 2 150 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment 20-009705 July 14, 2021 December 2022 June 2023 February 25, 2021 July 27, 2021 Mayo Clinic, Rochester, Minnesota, United States https://ClinicalTrials.gov/show/NCT04771611
NCT04685590 Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study SToMP-AD Not yet recruiting Alzheimer Disease, Early Onset|Mild Cognitive Impairment Drug: Dasatinib + Quercetin|Other: Placebo Capsules Serious Adverse Events (SAEs) and Adverse Events (AEs) in treatment group as compared to placebo group|Change in cellular senescence blood marker Senescence-Associated Secretory Phenotype (SASP) composite score|Change in cellular senescence blood marker Cluster of Differentiation 3 (CD3) in blood|Change in cellular senescence blood marker cyclin-dependent kinase inhibitor 2A (p16INK4A+) in blood|Change in cellular senescence blood marker T cells in blood|Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) slope|Change in the 14 - item Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-Cog 14) slope|Change in Positron Emission Tomography (PET) - Computed Tomography (CT) - brain tau pathology Wake Forest University Health Sciences|The University of Texas Health Science Center at San Antonio|Mayo Clinic All 65 Years and older   (Older Adult) Phase 2 48 Other Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment IRB00067429 October 2021 July 2026 July 2031 December 28, 2020 June 29, 2021 Wake Forest Health Sciences, Winston-Salem, North Carolina, United States https://ClinicalTrials.gov/show/NCT04685590
NCT04210986 Senolytic Drugs Attenuate Osteoarthritis-Related Articular Cartilage Degeneration: A Clinical Trial Active, not recruiting Osteoarthritis, Knee Dietary Supplement: Fisetin|Drug: Placebo oral capsule Incidence of Treatment-Emergent Adverse Events as assessed by blood chemistries (Liver)|Incidence of Treatment-Emergent Adverse Events as assessed by blood chemistries (Kidney)|Incidence of Treatment-Emergent Adverse Events as assessed by blood chemistries (Lysis Syndrome)|Change in levels of pro-inflammatory markers associated with Senescence|Change in levels of cartilage degenerating markers associated with OA|Change in physical function of the Study Knee (6 min walk)|Change in physical function of the Study Knee (timed-up-and-go test)|Change in physical function of the Study Knee (fast 40-meter walk)|Change in physical function of the Study Knee (LEK)|Change in physical function of the Study Knee (Chair Test)|Change in muscle strength (Isokinetic Dynamometry)|Evaluation of patient reported outcomes (PROs) for knee pain|Evaluation of patient reported outcomes (PROs) for knee function|Change in the quality of articular cartilage in the Study Knee with quantitative magnetic resonance imaging (MRI)|Change in time to conversion to alternative treatment Steadman Philippon Research Institute|United States Department of Defense|Office of Naval Research (ONR) All 40 Years to 80 Years   (Adult, Older Adult) Phase 1|Phase 2 100 Other|U.S. Fed Interventional Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment 2019-16 January 6, 2020 December 1, 2022 December 1, 2022 December 26, 2019 July 6, 2021 The Steadman Clinic, Vail, Colorado, United States https://ClinicalTrials.gov/show/NCT04210986
* All data provided by clinicaltrials.gov except publication and stored specimen columns. Data display last updated on Oct 25, 2021 6:00:00 AM